Company intelligence / Profile preview
BlueWillow Biologics
Ann Arbor, Michigan, United Statesbluewillow.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
BlueWillow has completed Phase 1 trials for their intranasal anthrax vaccine (BW-1010) with positive interim results showing safety, tolerability, and induction of systemic and mucosal immunity. Their H5N1 clinical trial has been completed with publication anticipated soon. The company's vaccines aim to elicit three-pronged mucosal, cellular, and systemic immune responses.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Intranasal vaccinesnanoemulsion-based vaccines
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Porton Biopharma Limited (UK)National Institute of Allergy and Infectious Diseases (NIAID)
Beyond the preview
Go deeper on BlueWillow Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BlueWillow Biologics.